secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001640334-26-000554
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo expands ART27.13 development for muscle preservation with GLP-1 therapies
--------------------------------------------------------------------------------

- ART27.13 to be evaluated as companion therapy to prevent muscle loss in patients on GLP-1 receptor agonists for weight reduction.
- Preclinical study initiated; provisional patent filed covering use of CB2 agonists with GLP-1 drugs.
- Independent research validated ART27.13 as a superagonist among 17 clinically studied CB2 agonists.
- Muscle protective effect observed in CAReS trial (cancer cachexia) and preclinical reversal of myotoxicity.
- J.P. Morgan projects global incretin market to reach $200B by 2030; ~25M Americans on GLP-1 by 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/0001640334-26-000554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033426000554/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-26-000554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer